maralixibat
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alagille Syndrome
Conditions
Alagille Syndrome
Trial Timeline
— → —
NCT ID
NCT04530994About maralixibat
maralixibat is a pre-clinical stage product being developed by Mirum Pharmaceuticals for Alagille Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04530994. Target conditions include Alagille Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04530994 | Pre-clinical | Completed |
| NCT07389031 | Phase 2 | Recruiting |
| NCT06553768 | Phase 3 | Recruiting |
| NCT04729751 | Phase 2 | Completed |
| NCT04524390 | Phase 2 | Completed |
| NCT04168385 | Phase 2 | Completed |
| NCT04185363 | Phase 3 | Completed |
| NCT03905330 | Phase 3 | Completed |
Competing Products
9 competing products in Alagille Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Odevixibat + Placebo | Ipsen | Phase 3 | 74 |
| Odevixibat | Ipsen | Phase 3 | 74 |
| LUM001 (Maralixibat) | Mirum Pharmaceuticals | Phase 2 | 49 |
| Livmarli + Livmarli | Mirum Pharmaceuticals | Pre-clinical | 20 |
| LUM001 (Maralixibat) | Mirum Pharmaceuticals | Phase 2 | 49 |
| LUM001 (Maralixibat) + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |
| Livmarli Oral Product | Mirum Pharmaceuticals | Approved | 82 |
| LUM001 + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |
| LUM001 + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |